Should you buy Insulet (PODD)?
Updated
Insulet Corporation combines best-in-class growth of 34% year-over-year with a perfect four-quarter earnings beat streak and a strong economic moat, but its current technical downtrend and failed momentum gate create a timing headwind that must resolve before the quality-growth combination can be fully valued.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Insulet has beaten consensus earnings in every one of the last four quarters with an average positive surprise of 15%, and revenue grew 34% year-over-year, indicating that operational execution is consistent and the growth runway remains intact. Earnings | Revenue growth remains above 25% and quarterly earnings beats continue in at least 3 of the next 4 quarters over the next 12 months. | →Stable |
| CounterHigh-growth medical device companies frequently face reimbursement headwinds and competitive entrants; sustaining 34% growth at scale becomes increasingly difficult. | ||
The business scores a perfect 9/9 Piotroski F-Score and meets the Rule of 40 threshold at 43, while the moat score of 8.2/10 signals durable competitive advantages that support high returns on capital over time. Quality breakdown | Gross margin holds above current levels and Piotroski F-Score stays at 8 or above over the next four reporting periods. | →Stable |
| CounterA significant share of quality advantage derives from the Omnipod platform concentration, meaning any regulatory setback or competitive substitute directly impairs the moat. | ||
Although MACD is showing improvement and RSI stands at 45, the stock remains below its 200-day moving average with the moving average slope at negative 8.0% per 30 days, meaning the technical recovery thesis requires a confirmed breakout above resistance to validate. Momentum breakdown | The stock rises above its 200-day moving average and momentum score rises above 5.0 within the next 6 months. | →Stable |
| CounterDeath cross conditions combined with falling on-balance volume suggest that institutional sellers may continue to dominate price action, keeping momentum weak for an extended period. | ||
Insulet has beaten consensus earnings in every one of the last four quarters with an average positive surprise of 15%, and revenue grew 34% year-over-year, indicating that operational execution is consistent and the growth runway remains intact.
→Stable- Expectation
- Revenue growth remains above 25% and quarterly earnings beats continue in at least 3 of the next 4 quarters over the next 12 months.
CounterHigh-growth medical device companies frequently face reimbursement headwinds and competitive entrants; sustaining 34% growth at scale becomes increasingly difficult.
The business scores a perfect 9/9 Piotroski F-Score and meets the Rule of 40 threshold at 43, while the moat score of 8.2/10 signals durable competitive advantages that support high returns on capital over time.
→Stable- Expectation
- Gross margin holds above current levels and Piotroski F-Score stays at 8 or above over the next four reporting periods.
CounterA significant share of quality advantage derives from the Omnipod platform concentration, meaning any regulatory setback or competitive substitute directly impairs the moat.
Although MACD is showing improvement and RSI stands at 45, the stock remains below its 200-day moving average with the moving average slope at negative 8.0% per 30 days, meaning the technical recovery thesis requires a confirmed breakout above resistance to validate.
→Stable- Expectation
- The stock rises above its 200-day moving average and momentum score rises above 5.0 within the next 6 months.
CounterDeath cross conditions combined with falling on-balance volume suggest that institutional sellers may continue to dominate price action, keeping momentum weak for an extended period.
▸ Show 1 more pillar▾ Show fewer
Reliance on the single Omnipod product platform and sole-sourced components represents a structural risk where disruption to either the product line or the supply chain could materially impair revenue with limited near-term substitution options.
→Stable- Expectation
- The company discloses supply chain diversification progress or new product-line contributions exceed 10% of revenue within 12 months.
CounterPlatform concentration has not historically harmed Insulet; the Omnipod system's clinical differentiation and installed base create switching costs that offset concentration risk.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Insulet has beaten consensus earnings in every one of the last four quarters with an average positive surprise of 15%, and revenue grew 34% year-over-year, indicating that operational execution is consistent and the growth runway remains intact.
Trip ifQuarterly EPS surprise falls below 0% in at least 2 of the next 4 quarters, signaling the beat streak has broken.
- P2The business scores a perfect 9/9 Piotroski F-Score and meets the Rule of 40 threshold at 43, while the moat score of 8.2/10 signals durable competitive advantages that support high returns on capital over time.
Trip ifPiotroski F-Score drops below 7 in any reporting period over the next 12 months.
- P3Although MACD is showing improvement and RSI stands at 45, the stock remains below its 200-day moving average with the moving average slope at negative 8.0% per 30 days, meaning the technical recovery thesis requires a confirmed breakout above resistance to validate.
Trip ifThe 200-day moving average slope remains below negative 5% for more than 6 consecutive months.
- P4Reliance on the single Omnipod product platform and sole-sourced components represents a structural risk where disruption to either the product line or the supply chain could materially impair revenue with limited near-term substitution options.
Trip ifRevenue from the Omnipod platform exceeds 95% of total revenue for 2 or more consecutive quarters, increasing concentration above current levels.
How the engine reached this verdict
TrendMatrix's engine output for Insulet Corporation (PODD) is STRONG_BUY_NOW with medium conviction, score 6.8/10 at $150.33. The C-path quality+growth combination cleared its gates — quality 7.6 and growth 10.0 — with 5.34 asymmetric R:R supporting the read.
The closest gate to its boundary is death cross (quality=7.6>=7.5+momentum=5.7>=5.0 exempted). A flip to BUY_WAIT requires either a gate slipping below its threshold or asymmetry R:R compressing below 2.0.
On the bull side: Strong earnings beat streak (4/4); High-quality business; Strong growth profile. On the bear side: Concentration risk — Product: Omnipod product platform; Concentration risk — Supplier: sole-sourced components; Below 200-MA, MA slope -9.1%/30d (confirmed downtrend).
The engine's suggested entry is $151.15 (current $150.33), target $218.19 (+44%), stop $140.56. Asymmetric reward-to-risk is 6.34. The engine's sizing output: 0.9% of portfolio at this asymmetry level (high-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PODD — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸High-quality business
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Product: Omnipod product platform
- ▸Concentration risk — Supplier: sole-sourced components
- ▸Below 200-MA, MA slope -9.1%/30d (confirmed downtrend)